Monitoring early breast cancer response to neoadjuvant therapy using H-scan ultrasound imaging

Preliminary preclinical results

Mawia Khairalseed, Kulsoom Javed, Gadhvi Jashkaran, Jung Whan Kim, Kevin J. Parker, Kenneth Hoyt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective—H-scan imaging is a new ultrasound technique used to visualize the relative size of acoustic scatterers. The purpose of this study was to evaluate the use of H-scan ultrasound imaging for monitoring early tumor response to neoadjuvant treatment using a preclinical breast cancer animal model. Methods—Real-time H-scan ultrasound imaging was implemented on a programmable ultrasound scanner (Vantage 256; Verasonics Inc., Kirkland, WA) equipped with an L11-4v transducer. Bioluminescence and H-scan ultrasound was used to image luciferase-positive breast cancer–bearing mice at baseline and at 24, 48, and 168 hours after administration of a single dose of neoadjuvant (paclitaxel) or sham treatment. Animals were euthanized at 48 or 168 hours, and tumors underwent histologic processing to identify cancer cell proliferation and apoptosis. Results—Baseline H-scan ultrasound images of control and therapy group tumors were comparable, but the latter exhibited significant changes over the 7-day study (P < .05). At termination, there was a marked difference between the H-scan ultrasound images of control and treated tumors (P < .05). Specifically, H-scan ultrasound images of treated tumors were more blue in hue than images obtained from control tumors. There was a significant linear correlation between the predominance of the blue hue found in the H-scan ultrasound images and intratumoral apoptotic activity (R 2 > 0.40, P < .04). Conclusion—Preliminary preclinical results suggest that H-scan ultrasound imaging is a new and promising tissue characterization modality. H-scan ultrasound imaging may provide prognostic value when monitoring early tumor response to neoadjuvant treatment.

Original languageEnglish (US)
Pages (from-to)1259-1268
Number of pages10
JournalJournal of Ultrasound in Medicine
Volume38
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Neoadjuvant Therapy
Ultrasonography
Breast Neoplasms
Neoplasms
Paclitaxel
Luciferases
Transducers
Acoustics
Breast
Animal Models
Placebos
Cell Proliferation
Apoptosis
Control Groups

Keywords

  • Apoptosis
  • Cancer
  • H-scan ultrasound
  • Neoadjuvant treatment
  • Ultrasound

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

Monitoring early breast cancer response to neoadjuvant therapy using H-scan ultrasound imaging : Preliminary preclinical results. / Khairalseed, Mawia; Javed, Kulsoom; Jashkaran, Gadhvi; Kim, Jung Whan; Parker, Kevin J.; Hoyt, Kenneth.

In: Journal of Ultrasound in Medicine, Vol. 38, No. 5, 01.05.2019, p. 1259-1268.

Research output: Contribution to journalArticle

Khairalseed, Mawia ; Javed, Kulsoom ; Jashkaran, Gadhvi ; Kim, Jung Whan ; Parker, Kevin J. ; Hoyt, Kenneth. / Monitoring early breast cancer response to neoadjuvant therapy using H-scan ultrasound imaging : Preliminary preclinical results. In: Journal of Ultrasound in Medicine. 2019 ; Vol. 38, No. 5. pp. 1259-1268.
@article{beaec35351674e37b2e545912caf4462,
title = "Monitoring early breast cancer response to neoadjuvant therapy using H-scan ultrasound imaging: Preliminary preclinical results",
abstract = "Objective—H-scan imaging is a new ultrasound technique used to visualize the relative size of acoustic scatterers. The purpose of this study was to evaluate the use of H-scan ultrasound imaging for monitoring early tumor response to neoadjuvant treatment using a preclinical breast cancer animal model. Methods—Real-time H-scan ultrasound imaging was implemented on a programmable ultrasound scanner (Vantage 256; Verasonics Inc., Kirkland, WA) equipped with an L11-4v transducer. Bioluminescence and H-scan ultrasound was used to image luciferase-positive breast cancer–bearing mice at baseline and at 24, 48, and 168 hours after administration of a single dose of neoadjuvant (paclitaxel) or sham treatment. Animals were euthanized at 48 or 168 hours, and tumors underwent histologic processing to identify cancer cell proliferation and apoptosis. Results—Baseline H-scan ultrasound images of control and therapy group tumors were comparable, but the latter exhibited significant changes over the 7-day study (P < .05). At termination, there was a marked difference between the H-scan ultrasound images of control and treated tumors (P < .05). Specifically, H-scan ultrasound images of treated tumors were more blue in hue than images obtained from control tumors. There was a significant linear correlation between the predominance of the blue hue found in the H-scan ultrasound images and intratumoral apoptotic activity (R 2 > 0.40, P < .04). Conclusion—Preliminary preclinical results suggest that H-scan ultrasound imaging is a new and promising tissue characterization modality. H-scan ultrasound imaging may provide prognostic value when monitoring early tumor response to neoadjuvant treatment.",
keywords = "Apoptosis, Cancer, H-scan ultrasound, Neoadjuvant treatment, Ultrasound",
author = "Mawia Khairalseed and Kulsoom Javed and Gadhvi Jashkaran and Kim, {Jung Whan} and Parker, {Kevin J.} and Kenneth Hoyt",
year = "2019",
month = "5",
day = "1",
doi = "10.1002/jum.14806",
language = "English (US)",
volume = "38",
pages = "1259--1268",
journal = "Journal of Ultrasound in Medicine",
issn = "0278-4297",
publisher = "American Institute of Ultrasound in Medicine",
number = "5",

}

TY - JOUR

T1 - Monitoring early breast cancer response to neoadjuvant therapy using H-scan ultrasound imaging

T2 - Preliminary preclinical results

AU - Khairalseed, Mawia

AU - Javed, Kulsoom

AU - Jashkaran, Gadhvi

AU - Kim, Jung Whan

AU - Parker, Kevin J.

AU - Hoyt, Kenneth

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Objective—H-scan imaging is a new ultrasound technique used to visualize the relative size of acoustic scatterers. The purpose of this study was to evaluate the use of H-scan ultrasound imaging for monitoring early tumor response to neoadjuvant treatment using a preclinical breast cancer animal model. Methods—Real-time H-scan ultrasound imaging was implemented on a programmable ultrasound scanner (Vantage 256; Verasonics Inc., Kirkland, WA) equipped with an L11-4v transducer. Bioluminescence and H-scan ultrasound was used to image luciferase-positive breast cancer–bearing mice at baseline and at 24, 48, and 168 hours after administration of a single dose of neoadjuvant (paclitaxel) or sham treatment. Animals were euthanized at 48 or 168 hours, and tumors underwent histologic processing to identify cancer cell proliferation and apoptosis. Results—Baseline H-scan ultrasound images of control and therapy group tumors were comparable, but the latter exhibited significant changes over the 7-day study (P < .05). At termination, there was a marked difference between the H-scan ultrasound images of control and treated tumors (P < .05). Specifically, H-scan ultrasound images of treated tumors were more blue in hue than images obtained from control tumors. There was a significant linear correlation between the predominance of the blue hue found in the H-scan ultrasound images and intratumoral apoptotic activity (R 2 > 0.40, P < .04). Conclusion—Preliminary preclinical results suggest that H-scan ultrasound imaging is a new and promising tissue characterization modality. H-scan ultrasound imaging may provide prognostic value when monitoring early tumor response to neoadjuvant treatment.

AB - Objective—H-scan imaging is a new ultrasound technique used to visualize the relative size of acoustic scatterers. The purpose of this study was to evaluate the use of H-scan ultrasound imaging for monitoring early tumor response to neoadjuvant treatment using a preclinical breast cancer animal model. Methods—Real-time H-scan ultrasound imaging was implemented on a programmable ultrasound scanner (Vantage 256; Verasonics Inc., Kirkland, WA) equipped with an L11-4v transducer. Bioluminescence and H-scan ultrasound was used to image luciferase-positive breast cancer–bearing mice at baseline and at 24, 48, and 168 hours after administration of a single dose of neoadjuvant (paclitaxel) or sham treatment. Animals were euthanized at 48 or 168 hours, and tumors underwent histologic processing to identify cancer cell proliferation and apoptosis. Results—Baseline H-scan ultrasound images of control and therapy group tumors were comparable, but the latter exhibited significant changes over the 7-day study (P < .05). At termination, there was a marked difference between the H-scan ultrasound images of control and treated tumors (P < .05). Specifically, H-scan ultrasound images of treated tumors were more blue in hue than images obtained from control tumors. There was a significant linear correlation between the predominance of the blue hue found in the H-scan ultrasound images and intratumoral apoptotic activity (R 2 > 0.40, P < .04). Conclusion—Preliminary preclinical results suggest that H-scan ultrasound imaging is a new and promising tissue characterization modality. H-scan ultrasound imaging may provide prognostic value when monitoring early tumor response to neoadjuvant treatment.

KW - Apoptosis

KW - Cancer

KW - H-scan ultrasound

KW - Neoadjuvant treatment

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85065000892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065000892&partnerID=8YFLogxK

U2 - 10.1002/jum.14806

DO - 10.1002/jum.14806

M3 - Article

VL - 38

SP - 1259

EP - 1268

JO - Journal of Ultrasound in Medicine

JF - Journal of Ultrasound in Medicine

SN - 0278-4297

IS - 5

ER -